Breviscapine reverses doxorubicin resistance in breast cancer and its related mechanisms
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Weijiang Fu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine & Shandong Key Laboratory Cardiovascular Proteomics, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Based on the effect of breviscapine (BRE) on reversing drug resistance of human breast cancer cell line MCF‐7/doxorubicin (Dox), the mechanism was preliminarily explored.
Methods
The methyl thiazolyl tetrazolium (MTT) method was introduced to detect inhibitory effect of Dox alone or in combination with BRE on MCF‐7 (M) and MCF‐7/Dox (MD) cells, and the inhibitory concentration (IC 50 ) was obtained. Cell apoptosis and Dox concentration was assessed by flow cytometry. The drug resistance multiple and reversal fold were calculated. Western blot was performed to evaluate the expression of Bcl‐2, Bax, EGFR, p‐EGFR, P‐gp, caspase‐3, and cleaved‐caspase‐3 protein in cells. The efflux of Rho‐123 was measured by flow cytometry and fluorescence microscopy.
Results
The IC 50 of Dox on MD and M cells was 16.67 and 0.71 μg/mL, respectively, with a drug resistance ratio of 23.48 times. The IC 50 of Dox combined with BRE on MD cells was 5.62 μg/mL, with a reversal ratio of 2.97 times. BRE greatly enhanced Dox‐induced apoptosis of MD cells. Bax and cleaved‐caspase‐3 (proapoptotic protein) expression were obviously increased, while Bcl‐2 (antiapoptotic protein) expression was significantly decreased after BRE treatment. BRE inhibited EGFR activation and P‐gp expression. BRE increased the intracellular accumulation of Dox in MD cells by P‐gp.
Conclusion
BRE could increase the MD sensitivity to Dox via increasing Bax and cleaved‐caspase‐3 expression and inhibiting Bcl‐2 expression, thereby promoting cell apoptosis. BRE reversed Dox resistance of MD cells by increasing Dox intracellular accumulation through inhibiting P‐gp expression via EGFR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine & Shandong Key Laboratory Cardiovascular Proteomics, Qilu Hospital of Shandong University, Jinan, China.
- Department of Medical Insurance, Qilu Hospital of Shandong University, Jinan, China.
- Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, China.
ORCID-Profile: Haiying Li
Zitieren
APA
Fu, W., Song, J., & Li, H. (2023). Breviscapine reverses doxorubicin resistance in breast cancer and its related mechanisms. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15072
Vancouver
Fu W, Song J, Li H. Breviscapine reverses doxorubicin resistance in breast cancer and its related mechanisms. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15072
BibTeX
@article{Fu2023,
author = {Fu, Weijiang and Song, Jie and Li, Haiying},
title = {Breviscapine reverses doxorubicin resistance in breast cancer and its related mechanisms},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15072}
}
EUVIMED